Printer Friendly

Bioniche granted European patent for mycobacterial cell wall-DNA complex as prostate cancer treatment.

Bioniche Life Sciences, Inc. (Belleville, Canada) has had another patent granted on its core technology: Mycobacterial Cell Wall-DNA Complex (MCC). The European Patent Organization granted the patent: "Composition and Method for Inducing Apoptosis in Prostate Cancer Cells" (EPO1165106)

"This patent provides protection for the use of mycobacterial DNA and Mycobacterial Cell Wall-DNA complex (MCC) as a means of inducing programmed cell death (apoptosis) in prostate cancer cells," noted Dr. Nigel C. Phillips, Chief Scientific Officer at Bioniche Life Sciences Inc. and patent co- inventor. "This technology, therefore, has application in the treatment of prostate cancer independent of the stage of the disease or of the hormone sensitivity of the cancer cells. The application fields for the company's core mycobacterial cell wall technology platform now encompass immune stimulation, anticancer therapy, and the treatment of a range of inflammatory disorders. It also complements other technology platforms within the company that are either commercialized or under development."

Prostate cancer is the most common form of cancer among men in the United States, with about 240,000 new cases diagnosed annually in that country alone. Worldwide, prostate cancer ranks second in cancer incidence (680,000) and fourth in cancer mortality among men(1). "MCC could offer a positive alternative to current treatments, which often have limiting side effects," noted Dr. Mario C. Filion, Head of Biomedical Research at Bioniche Life Sciences Inc.

Graeme McRae, President & CEO of Bioniche Life Sciences Inc., stated, "The mycobacterial cell wall technology is the core of our product development pipeline. The latest formulation of the technology - MCC - is being targeted for the treatment of bladder cancer initially, with a Phase III clinical trial planned in North America and Europe. We have already conducted a Phase I clinical study for prostate cancer and plan to initiate further studies once the bladder cancer Phase III trial is underway."

The core mycobacterial cell wall technology platform at Bioniche comprises compositions with antiviral, immune adjuvant, and immune stimulatory activity, as well as chemotherapeutic activity against cancer cells. A number of compositions are commercialized for use in veterinary applications, and the company is actively developing compositions for use in a number of human applications.

Bioniche discovers, develops, manufactures, and markets proprietary products for human and animal health markets worldwide. The fully-integrated company employs more than 300 individuals and has three principal operating divisions: Animal Health, Food Safety, and Human Health, which includes Bioniche Therapeutics and Bioniche Pharma Group.

Bioniche Life Sciences Inc.

+1-613-966-8058

www.Bioniche.com
COPYRIGHT 2005 Biotech Patent News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Comment:Bioniche granted European patent for mycobacterial cell wall-DNA complex as prostate cancer treatment.
Publication:BIOTECH Patent News
Geographic Code:1CANA
Date:May 1, 2005
Words:412
Previous Article:Applied Imaging collaborates with University of Vermont College of Medicine.
Next Article:New patent covers Targeted Genetics' approach to increase carrying capacity of AAV vectors.
Topics:


Related Articles
Vical obtains angiogenesis patent.
Introgen's anti-cancer therapy in combination with established cancer treatments awarded patent.
Vical announces issuance of patent for gene-based cancer therapy.
Cell Genesys issued patent for oncolytic virus.
CytRx forms prostate cancer alliance with Cytogen and Progenics.
Vical granted key DNA vaccine patent in Europe.
Vical announces issuance of European patents covering platform technology.
Bioniche mycobacterial cell wall extract granted new patent for production performance in animals - mycobacterial cell wall technology continues to...
SATRAPLATIN REDUCES RISK OF PROSTATE CANCER PROGRESSION.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters